Two analyst upgrades on Friday, a new CEO and a 33% increase in its stock price since November may be confirmation that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is finally rebounding.
The Israeli-based maker of generic drugs has struggled for the past few years amid CEO turmoil, middling performance and, especially, its $6.8 billion acquisition of specialty drug maker Cephalon, which has not contributed much to profit.
Once an investor darling, the company’s generic growth was hit because fewer branded drugs were coming off patent. Meanwhile, patents were expiring on Teva’s top-selling branded product, multiple sclerosis drug Copaxone.
Worse, then-CEO Jeremy Levin came on board in December 2012 promising to turn around the company. Instead, he became embroiled in disputes with his board and was gone in 10 months.
What is different now is that investors and the board like the new CEO, Erez Vigodman. He had been a director himself but has experience turning around struggling companies.
The company has pledged to cut $2 billion in costs by 2017. Even if Copaxone goes off patent on June 1, it is not clear if generic versions will deliver the same results to patients. Plus, the company has succeeded in moving some Copaxone patients to newer versions of the drug.
The consensus is that Teva will earn $4.53 a share in 2014 and $4.50 in 2015, with revenue in both years flat at around $19 billion. The company earned $5.01 in 2013. But if no generics to Copaxone reach market, Teva says earnings this year could hit $4.80 to $5.10. Revenue could top $20 billion.
The shares fell by nearly half between 2010 and September 2011. They did not start to move again until Levin was gone. In the fourth quarter, George Soros’s Soros Fund Management added 5.7 million shares to its stake. The shares were trading at $48.76, up 1.6%, on Friday and just below its 52-week high.
If the company is able to show its turnaround is real, analysts think the stock could move 30% or so higher, in line with rivals Mylan Inc. (NYSE: MYL) and Activis PLC (NYSE: ACT). That’s a big if, but the gains since November suggest investors like the odds.
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.